Trevi Therapeutics (TRVI) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free TRVI Stock Alerts $2.57 -0.02 (-0.77%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 6:24 AM | americanbankingnews.comThomas Sciascia Sells 53,368 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) StockJune 1 at 9:22 AM | insidertrades.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Sells $136,088.40 in StockMay 26, 2024 | americanbankingnews.comLisa Delfini Sells 4,350 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) StockMay 25, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CFO Sells 4,350 Shares of StockMay 23, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 25,037 Shares of StockMay 22, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $71,605.82 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 25,037 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $2.86, for a total value of $71,605.82. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $610,075.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.May 15, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,578 Shares of StockMay 14, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $13,276.20 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,578 shares of the company's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $2.90, for a total value of $13,276.20. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $618,607.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.May 13, 2024 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call TranscriptMay 12, 2024 | uk.investing.comEarnings call: Trevi Therapeutics reports progress in clinical trialsMay 12, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | marketbeat.comFY2024 EPS Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) Cut by Leerink PartnrsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a report released on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the company will postMay 9, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming ConferencesMay 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)May 8, 2024 | finance.yahoo.comQ1 2024 Trevi Therapeutics Inc Earnings CallMay 8, 2024 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday.May 7, 2024 | investorplace.comTRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Q1 2024 Financial Results: A Detailed AnalysisMay 7, 2024 | prnewswire.comTrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 2, 2024 | marketbeat.comTrevi Therapeutics (TRVI) Scheduled to Post Quarterly Earnings on TuesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.May 1, 2024 | yahoo.comGloria Trevi Clears First Hurdle for Lawsuit Claiming She Was Main Victim of Sex AbuseMay 1, 2024 | prnewswire.comTrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024April 9, 2024 | finance.yahoo.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 9, 2024 | prnewswire.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 4, 2024 | uk.investing.comTrevi Therapeutics appoints new VP for clinical developmentApril 4, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming April EventsApril 2, 2024 | finance.yahoo.comTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership TeamMarch 29, 2024 | msn.comTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itMarch 28, 2024 | msn.comTrevi Italian Restaurant at Forum Shops unexpectedly closesMarch 27, 2024 | msn.comProminent Trevi Italian Restaurant Abruptly Closes at the Forum ShopsMarch 21, 2024 | insidermonkey.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Trevi Therapeutics (NASDAQ:TRVI)Oppenheimer reissued an "outperform" rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research report on Thursday.March 21, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdatesMarch 20, 2024 | benzinga.comTrevi Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023March 20, 2024 | finance.yahoo.comTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical TrialsMarch 17, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With NebulossaMarch 16, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With NebulossaMarch 14, 2024 | marketbeat.comTrevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, March 20, Zacks reports.March 13, 2024 | finance.yahoo.comTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024March 7, 2024 | msn.comOne million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?February 29, 2024 | finance.yahoo.comprivate equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last weekFebruary 28, 2024 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 28, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 24, 2024 | thestreet.comTrevi Therapeutics Inc.February 22, 2024 | finance.yahoo.comTRVI Mar 2024 2.000 callFebruary 18, 2024 | finance.yahoo.comTRVI Mar 2024 3.000 callFebruary 8, 2024 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at Leerink Partnrs reduced their FY2024 earnings estimates for shares of Trevi Therapeutics in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0February 7, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) to Post Q1 2024 Earnings of ($0.09) Per Share, Leerink Partnrs ForecastsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company wil Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. TRVI Media Mentions By Week TRVI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼1.210.76▲Average Medical News Sentiment TRVI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼52▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VNDA News CARA News SAGE News LYEL News SLN News HROW News ALXO News DNTH News ANAB News AVBP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.